@dr-jayne-ellis.bsky.social
AHD clinical researcher, Infectious Diseases Institute, Kampala, Uganda
Wellcome Global Health Research Clinical PhD Fellow, LSHTM
Infectious Disease/Micro trainee, UCLH
Wellcome Global Health Research Clinical PhD Fellow, LSHTM
Infectious Disease/Micro trainee, UCLH
93% achieved HIV virological suppression by 32-weeks post
1HP, and there were no cases of cryptococcal relapse.
1HP, and there were no cases of cryptococcal relapse.
July 16, 2025 at 1:24 PM
93% achieved HIV virological suppression by 32-weeks post
1HP, and there were no cases of cryptococcal relapse.
1HP, and there were no cases of cryptococcal relapse.
Day-14 dolutegravir C24h geometric mean (trough level)
was 0.61 (95%CI 0.32-1.16) mg/L, 9-fold higher than the
dolutegravir IC90 of 0.064 mg/L
was 0.61 (95%CI 0.32-1.16) mg/L, 9-fold higher than the
dolutegravir IC90 of 0.064 mg/L
July 16, 2025 at 1:24 PM
Day-14 dolutegravir C24h geometric mean (trough level)
was 0.61 (95%CI 0.32-1.16) mg/L, 9-fold higher than the
dolutegravir IC90 of 0.064 mg/L
was 0.61 (95%CI 0.32-1.16) mg/L, 9-fold higher than the
dolutegravir IC90 of 0.064 mg/L
Despite expected reductions in exposure, once-daily 50mg
dolutegravir and 800mg fluconazole dosing may be safe and
effective during 1HP amongst adults with advanced HIV
disease receiving treatment for cryptococcal meningitis.
dolutegravir and 800mg fluconazole dosing may be safe and
effective during 1HP amongst adults with advanced HIV
disease receiving treatment for cryptococcal meningitis.
July 16, 2025 at 1:16 PM
Despite expected reductions in exposure, once-daily 50mg
dolutegravir and 800mg fluconazole dosing may be safe and
effective during 1HP amongst adults with advanced HIV
disease receiving treatment for cryptococcal meningitis.
dolutegravir and 800mg fluconazole dosing may be safe and
effective during 1HP amongst adults with advanced HIV
disease receiving treatment for cryptococcal meningitis.